Partner HGSI Files Benlysta For US Approval: GSK
First potentially new treatment in decades for the hard-to-treat autoimmune disease lupus might be on the shelves soon as GlaxoSmithKline Plc (GSK) on Thursday said partner Human Genome Sciences Inc. (HGSI) has applied for U. S. regulatory approval for their jointly-developed drug Benlysta.
As of now no where in the world Benlysta, or belimumab, is approved or licensed but there are high hopes for the treatment by the U. K. drug maker and its Rockville, Md.-based partner. An application earlier this month was submitted to the FDA for a Biologics License to Europe's drug regulator for marketing approval there.
H. Thomas Watkins, President and Chief Executive Officer of Human Genome Sciences, said, "Based on the results of our pivotal Phase 3 studies, we believe Benlysta has the potential to become the first new approved drug for systemic lupus in more than 50 years."
The drug can be expected in the market late this year or in early 2011.
New Zealand News
- Tesla to design & build affordable EV in China: Tom Zhu
- First deliveries of all-electric Porsche in Australia to take place this weekend
- Crown Resorts suffers record six-month loss due to COVID-19 closures
- Australia’s Crown Resorts 'not suitable' for Sydney gaming license: Inquiry Commission
- What Does Phasing Out Cheques Tell Us About Finance in New Zealand?